Display options
Cite
Guelcher SA, Sterling JA. Contribution of bone tissue modulus to breast cancer metastasis to bone. Cancer Microenviron. 2011;4(3):247-59doi: 10.1007/s12307-011-0078-3.
Guelcher, S. A., & Sterling, J. A. (2011). Contribution of bone tissue modulus to breast cancer metastasis to bone. Cancer microenvironment : official journal of the International Cancer Microenvironment Society, 4(3), 247-59. https://doi.org/10.1007/s12307-011-0078-3
Guelcher, Scott A, and Sterling, Julie A. "Contribution of bone tissue modulus to breast cancer metastasis to bone." Cancer microenvironment : official journal of the International Cancer Microenvironment Society vol. 4,3 (2011): 247-59. doi: https://doi.org/10.1007/s12307-011-0078-3
Guelcher SA, Sterling JA. Contribution of bone tissue modulus to breast cancer metastasis to bone. Cancer Microenviron. 2011 Dec;4(3):247-59. doi: 10.1007/s12307-011-0078-3. Epub 2011 Jul 26. PMID: 21789687; PMCID: PMC3234324.
Copy Download .nbib Format: NLM
Share it on

Cancer Microenviron. 2011 Dec;4(3):247-59. doi: 10.1007/s12307-011-0078-3. Epub 2011 Jul 26.

Contribution of bone tissue modulus to breast cancer metastasis to bone.

Cancer microenvironment : official journal of the International Cancer Microenvironment Society

Scott A Guelcher, Julie A Sterling

Affiliations

  1. Department of Chemical and Biomolecular Engineering, Vanderbilt University, 2400 Highland Avenue, 107 Olin Hall, Nashville, TN, 37235-1604, USA, [email protected].

PMID: 21789687 PMCID: PMC3234324 DOI: 10.1007/s12307-011-0078-3

Abstract

Certain tumors, such as breast, frequently metastasize to bone where they can induce bone destruction. Currently, it is well-accepted that the tumor cells are influenced by other cells and growth factors present in the bone microenvironment that lead to tumor-induced bone disease. Over the past 20 years, many groups have studied this process and determined the major contributing factors; however, these results do not fully explain the changes in gene expression and cell behavior that occur when tumor cells metastasize to bone. More recently, groups studying metastasis from soft tissue sites have determined that the rigidity of the microenvironment, which increases during tumor progression in soft tissue, can regulate tumor cell behavior and gene expression. Therefore, we began to investigate the role of the rigid bone extracellular matrix in the regulation of genes that stimulate tumor-induced bone disease. We found that the rigidity of bone specifically regulates parathyroid hormone-related protein (PTHrP) and Gli2 expression in a transforming growth factor β (TGF-β) and mechanotransduction-dependent mechanism. In this review, we summarize the mechanotransduction signaling pathway and how this influences TGF-β signaling and osteolytic gene expression.

References

  1. J Cell Biol. 1995 Oct;131(2):539-49 - PubMed
  2. Breast Cancer Res Treat. 1994;32(1):73-84 - PubMed
  3. Breast Cancer Res. 2006;8(4):R42 - PubMed
  4. Bone. 2003 Jul;33(1):28-37 - PubMed
  5. Science. 2005 Nov 18;310(5751):1139-43 - PubMed
  6. J Biomech. 2000 Jan;33(1):15-22 - PubMed
  7. Curr Opin Cell Biol. 2008 Apr;20(2):242-8 - PubMed
  8. EMBO J. 2000 Mar 1;19(5):964-78 - PubMed
  9. Proc Natl Acad Sci U S A. 1992 Jun 15;89(12):5326-30 - PubMed
  10. Clin Cancer Res. 2006 Mar 1;12(5):1398-401 - PubMed
  11. Cancer Cell. 2005 Sep;8(3):175-6 - PubMed
  12. Int J Cancer. 1997 Dec 10;73(6):812-5 - PubMed
  13. PLoS One. 2009;4(4):e5275 - PubMed
  14. Cancer Res. 2007 Apr 15;67(8):3752-8 - PubMed
  15. Oncogene. 2007 Sep 13;26(42):6238-43 - PubMed
  16. J Clin Oncol. 2010 Jun 1;28(16):2712-8 - PubMed
  17. Nature. 2005 Apr 21;434(7036):1040-5 - PubMed
  18. Proc Soc Exp Biol Med. 1999 Nov;222(2):124-38 - PubMed
  19. Int J Oncol. 1998 Jan;12(1):87-94 - PubMed
  20. Dev Cell. 2010 Aug 17;19(2):194-206 - PubMed
  21. Lancet. 2011 Mar 5;377(9768):813-22 - PubMed
  22. J Bone Miner Res. 2009 May;24(5):886-98 - PubMed
  23. Nat Cell Biol. 2008 Sep;10(9):1062-8 - PubMed
  24. J Cell Sci. 2009 Apr 15;122(Pt 8):1059-69 - PubMed
  25. J Endocrinol. 2007 Jan;192(1):131-40 - PubMed
  26. Vasc Health Risk Manag. 2009;5:663-71 - PubMed
  27. J Cell Sci. 2006 Feb 1;119(Pt 3):508-18 - PubMed
  28. Proc Natl Acad Sci U S A. 2007 May 15;104(20):8455-60 - PubMed
  29. J Immunother. 2010 Apr;33(3):316-25 - PubMed
  30. J Cell Biol. 2002 Nov 25;159(4):695-705 - PubMed
  31. J Bone Miner Res. 2005 Aug;20(8):1454-61 - PubMed
  32. Lab Invest. 1997 Dec;77(6):665-75 - PubMed
  33. Cancer Res. 2003 Aug 15;63(16):5028-33 - PubMed
  34. J Cell Sci. 2007 May 15;120(Pt 10):1801-9 - PubMed
  35. J Orthop Sci. 2000;5(1):75-81 - PubMed
  36. Biophys J. 2006 Mar 1;90(5):1804-9 - PubMed
  37. Bone. 2011 Jan;48(1):6-15 - PubMed
  38. Endocrinology. 1994 Apr;134(4):1936-42 - PubMed
  39. EMBO J. 1993 Oct;12(10):3789-98 - PubMed
  40. Breast Cancer Res Treat. 2011 Jun;127(2):429-38 - PubMed
  41. J Biol Chem. 1994 Jul 8;269(27):17911-7 - PubMed
  42. J Cell Biol. 2003 Apr 14;161(1):143-53 - PubMed
  43. Endocrinology. 1994 May;134(5):2230-6 - PubMed
  44. J Bone Miner Res. 2011 Jan;26(1):100-12 - PubMed
  45. Cell. 2002 Jul 26;110(2):139-42 - PubMed
  46. J Cell Physiol. 1998 Aug;176(2):424-34 - PubMed
  47. Cancer Res. 2011 Jan 1;71(1):175-84 - PubMed
  48. J Clin Invest. 1999 Jan;103(2):197-206 - PubMed
  49. Anticancer Res. 2005 Jan-Feb;25(1A):79-83 - PubMed
  50. J Biol Chem. 1998 Feb 27;273(9):5081-5 - PubMed
  51. Mol Cancer. 2010 May 26;9:122 - PubMed
  52. Science. 1993 May 21;260(5111):1124-7 - PubMed
  53. Clin Exp Metastasis. 2004;21(2):119-28 - PubMed
  54. Diagn Mol Pathol. 1996 Jun;5(2):127-35 - PubMed
  55. Cancer Res. 2007 Jun 15;67(12):5821-30 - PubMed
  56. Breast Cancer Res. 2006;8(2):R20 - PubMed
  57. J Biol Chem. 2004 Mar 26;279(13):12001-4 - PubMed
  58. J Dent Res. 2005 Jan;84(1):64-8 - PubMed
  59. Nat Cell Biol. 1999 Aug;1(4):200-6 - PubMed
  60. J Clin Invest. 2002 Nov;110(10):1559-72 - PubMed
  61. Curr Osteoporos Rep. 2006 Mar;4(1):28-33 - PubMed
  62. Osteoporos Int. 2003;14 Suppl 3:S35-42 - PubMed
  63. Cancer Res. 2006 Aug 1;66(15):7548-53 - PubMed
  64. J Cell Sci. 2006 Oct 1;119(Pt 19):3901-3 - PubMed
  65. Cancer. 2000 Jun 15;88(12 Suppl):2892-8 - PubMed
  66. Proc Natl Acad Sci U S A. 2005 Feb 1;102(5):1454-9 - PubMed
  67. Cell. 1997 Jan 10;88(1):39-48 - PubMed
  68. FASEB J. 2002 Aug;16(10):1266-8 - PubMed
  69. Bone. 2011 Jan;48(1):54-65 - PubMed
  70. Cell. 2006 Aug 25;126(4):677-89 - PubMed
  71. J Clin Invest. 2007 May;117(5):1305-13 - PubMed
  72. Mol Cell Biol. 2005 Oct;25(19):8581-91 - PubMed
  73. Science. 1978 May 12;200(4342):618-27 - PubMed
  74. Proc Natl Acad Sci U S A. 2008 May 6;105(18):6626-31 - PubMed
  75. Development. 1998 Apr;125(7):1285-94 - PubMed
  76. J Cell Biol. 1988 Oct;107(4):1385-96 - PubMed
  77. Endocrinology. 2003 Dec;144(12):5521-9 - PubMed
  78. Anticancer Res. 2006 May-Jun;26(3A):1893-901 - PubMed
  79. Eur J Cancer. 2000 Feb;36(3):397-409 - PubMed
  80. Biomaterials. 2010 Aug;31(24):6131-41 - PubMed
  81. J Colloid Interface Sci. 2011 Mar 15;355(2):503-8 - PubMed
  82. Endocr Rev. 1998 Feb;19(1):18-54 - PubMed
  83. Biomaterials. 2008 Apr;29(12):1762-75 - PubMed
  84. Exp Cell Res. 1997 Jan 10;230(1):111-20 - PubMed
  85. Nat Rev Cancer. 2010 Jan;10(1):9-22 - PubMed
  86. J Clin Invest. 1999 Aug;104(4):399-407 - PubMed
  87. Cell. 2006 Dec 1;127(5):1015-26 - PubMed
  88. Biophys J. 2005 Dec;89(6):L52-4 - PubMed
  89. Breast Cancer Res Treat. 2009 Jun;115(3):453-95 - PubMed
  90. J Clin Invest. 1997 May 1;99(9):2284-92 - PubMed
  91. Cell Motil Cytoskeleton. 2005 Jan;60(1):24-34 - PubMed
  92. N Engl J Med. 2010 May 13;362(19):1825-7 - PubMed
  93. J Biol Chem. 2002 Jul 5;277(27):24571-8 - PubMed
  94. Nat Rev Cancer. 2009 Feb;9(2):108-22 - PubMed
  95. Cancer Cell. 2003 Jun;3(6):537-49 - PubMed
  96. Cancer Cell. 2005 Sep;8(3):241-54 - PubMed
  97. Org Biomol Chem. 2010 Jan 21;8(2):299-304 - PubMed
  98. J Mammary Gland Biol Neoplasia. 2004 Oct;9(4):325-42 - PubMed
  99. J Bone Miner Res. 2010 Nov;25(11):2419-26 - PubMed
  100. N Engl J Med. 1988 Sep 1;319(9):556-63 - PubMed
  101. N Engl J Med. 2010 May 13;362(19):1761-71 - PubMed
  102. Nature. 2010 Nov 4;468(7320):103-7 - PubMed
  103. J Cell Physiol. 2007 Dec;213(3):565-73 - PubMed
  104. Cancer Res. 2005 Dec 1;65(23):11001-9 - PubMed
  105. Invest New Drugs. 2012 Jun;30(3):1074-81 - PubMed
  106. Cancer Res. 2011 Feb 1;71(3):822-31 - PubMed
  107. Curr Osteoporos Rep. 2011 Jun;9(2):89-95 - PubMed
  108. J Clin Invest. 1995 Oct;96(4):1815-22 - PubMed
  109. J Clin Invest. 1996 Oct 1;98(7):1544-9 - PubMed
  110. Proc Natl Acad Sci U S A. 1990 Sep;87(18):6969-73 - PubMed
  111. J Cell Biol. 2003 Oct 27;163(2):409-19 - PubMed
  112. Proc Natl Acad Sci U S A. 2006 Jul 18;103(29):10889-94 - PubMed
  113. J Bone Miner Metab. 2007;25(6):337-44 - PubMed
  114. Biophys J. 2008 Sep;95(5):2203-18 - PubMed
  115. Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6291s-6295s - PubMed
  116. Cancer Res. 1991 Jun 1;51(11):3059-61 - PubMed
  117. Annu Rev Immunol. 2007;25:619-47 - PubMed
  118. Eur J Surg Oncol. 1996 Jun;22(3):254-8 - PubMed
  119. PLoS One. 2010 Nov 15;5(11):e15451 - PubMed
  120. Annu Rev Cell Dev Biol. 2003;19:677-95 - PubMed
  121. Curr Biol. 2008 Sep 9;18(17):1295-1299 - PubMed
  122. Cancer Res. 1990 Dec 1;50(23):7710-6 - PubMed

Publication Types